ClinicalTrials.gg
RecruitingNCT07366879Updated May 13, 2026

Exercise Intervention as an Adjunct to Medical Therapy in Newly Diagnosed Patients With Pulmonary Arterial Hypertension

An interventional study of Home-based, remotely delivered, supervised Exercise programme in Pulmonary Arterial Hypertension, sponsored by Golden Jubilee National Hospital. Recruiting at 1 site in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-13.

Sponsored by Golden Jubilee National Hospital · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Apr 2026; still recruiting 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 98 studies in Pulmonary Arterial Hypertension with a site in United Kingdom — 11 open to participants now, 18 under way, 6 of them phase 3. Pulmonary Arterial Hypertension · United Kingdom.

Planned enrollment
70th of 91
40 · median 108
Started
2026
with 4 others
No phase
6 of 98
1 open now
Primary completion
2027-08
later than 7 of 17 live
Registered
96th of 98
by date

Among the 98 studies in Pulmonary Arterial Hypertension with a site in United Kingdom, this one is the 70th largest by planned enrollment of the 91 interventional ones that give a count, is one of 5 that started in 2026, is one of 6 with no phase, reaches primary completion later than 7 of the 17 other live ones, and was the 96th registered.

Pulmonary Arterial Hypertension

701 studies on the registry are indexed under Pulmonary Arterial Hypertension; 141 are open to participants now.

Browse Pulmonary Arterial Hypertension studies →

Open to participants now

11 of the 98 studies in Pulmonary Arterial Hypertension with a site in United Kingdom are open now. Recruiting first, the newest first:

5 more — sign in →

All 11 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 90 Pulmonary Arterial Hypertension studies recruiting now, 51 (57%) set no upper age limit and 24 (27%) stop at 75 or younger; 18 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 98 studies in Pulmonary Arterial Hypertension with a site in United Kingdom, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn if an exercise programme started shortly after diagnosis improves the fitness and mental wellbeing of patients with pulmonary hypertenion over and above medication alone. It will also learn about whether extra support can help patients keep up with exercise in the long term. The main questions it aims to answer are:

  • Doe exercise improve how far patients can walk over six minutes
  • Does exercise improve quality of life scores
  • Does exercise improve mental health scores
  • Does extra support after an exercise programme help patients to continue exercising in the long term

Researchers will compare the exercise programme to a control group (a group of similar patients who do not receive the exercise programme) to see the effect that exercise has.

Participants in the exercise programme group will:

  • Undergo an exercise programme for 12 weeks, starting around 3 months after their diagnosis
  • They will undertake the exercise programme at home, remotely supervised by the research team with regular contact
  • Visit the clinic at the end of the programme for checkups and tests
  • Keep a diary of their exercise and how they are feeling

Participants in the control group will:

-Still undergo the exercise programme, but this will happen at a delayed time, starting around 6 months after diagnosis, to allow for a comparison between the two groups.

Following completion of the exerise programme:

  • Half of participants will receive extra support to help them continue to exercise
  • The other half will not receive any additional support
  • All patients will be reviewed 1 year following the completion of their exercise programme to monitor their ongoing exercise levels.
Read the detailed description

This study is designed to deliver a remotely supervised, home-based exercise programme to patients newly diagnosed with pulmonary arterial hypertension with a view to early optimisation of their condition. The design is a waitlist randomised controlled trial whereby participants will be randomised to an exercise intervention or control group, with the control group then going on to have access to the exercise programme after a 12-week delay. There will be further randomisation after completion of the exercise programme to determine if participants have access to support package aimed at improving adherence to exercise.

The study objectives are to evaluate:

  • The incremental effect of an exercise programme on exercise capacity, quality of life and mental health
  • The impact of an additional support package following completion of the exercise programme on adherence to exercise in the long term.

Methodology Patients will be recruited from the Scottish Pulmonary Vascular Unit and consented for the study at the time of diagnosis with pulmonary arterial hypertension.

Participants will be commenced on pulmonary vasodilator therapy as per standard of care decided by the clinical team, then will be reviewed 3 months later at outpatient clinic.

Half of participants will then be randomly assigned to an intervention group and the remaining half to a control group. The intervention group will start a 12-week home-based remotely supervised exercise programme while the control group continue on medical therapy alone to allow for comparison. After this 12 weeks, participants in both groups will be seen back in clinic for further review and data collection. The control group will then commence the exercise programme.

After each participant completes the exercise programme they will then be randomly assigned to either receive a support package from the research team, designed to improve adherence to exercise, or to act as a control group and continue with self-directed exercise. All participants will be reviewed one year after completing the exercise programme to review their adherence to exercise.

Data collection:

Data will be collected at standard of care outpatient clinic appointments (six-minute walk test results, EmPHasis-10 questionnaires, NT-proBNP test. Study questionnaires will also be checked at these visits (PHQ-9 and GAD-7 questionnaires at all visits, exercise adherence rating scale questionnaire at the final visits).

Smartwatches will also be worn by study participants and data will be collected on step count, exercise frequency and intensity, heart rate variability, sleep.

Qualitative data will be gathered from the participants by interview at the end of the exercise programme and following their follow-up phase to evaluate factors that helped or hindered exercise.

Exercise programme:

The exercise programme is carried out fully remotely and has been adopted from the PHAHB study by McCormack et al 2019 and includes induction training sessions (discussing the introduction to exercise equipment, the provided materials, exercise safety and demonstrations) and health coaching sessions (discussing various topics including benefits of exercise, goal setting, action planning, self-monitoring, identification and management of barriers to exercise, problem solving and feedback on behaviour).

There are three types of training activities in the programme which are aerobic training (either walking, cycling or a combination), resistance training (using body weight exercises, but may progress to using resistance bands or light weights) and respiratory training. These activities are built up gradually throughout the programme on an individualised basis over a 12-week period.

Exercise support package:

The exercise adherence package will consist of access to online exercise resources, monthly phone calls from the research team and a forum to allow participant discussion and encouragement.

Sample size: Recruitment target is 40 patients with a 1:1 randomisation to the intervention and control groups.

03

Conditions studied

  • Pulmonary Arterial Hypertension

Keywords

  • pulmonary arterial hypertension
  • PAH
  • pulmonary hypertension
  • exercise training
  • exercise adherence
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged 18-years-old and above
  • Diagnosed with pulmonary hypertension (group I and non-operable group IV) by right heart catheterisation showing:

    • a baseline mean pulmonary artery pressure >20mmHg
    • pulmonary vascular resistance >2 Wood Units
    • pulmonary capillary wedge pressure \<15mmHg
  • Able to provide written

Exclusion criteria

Exclusion Criteria:

  • Diagnosis with pulmonary hypertension of any other cause

    • Group II (PH due to left heart disease)
    • Group III (PH due to hypoxic lung disease)
    • Operable group IV (PH due to chronic thromboembolic disease amenable to surgical treatment)
    • Group V (unclear and/or multifactorial elements).
  • Planned treatment with a research trial medication during the study timeframe
  • Consenting clinician and/or patient concern regarding the patient's safety in performing a home-based exercise programme
  • Patients with syncopal episodes felt to be related to pulmonary hypertension at time of exercise intervention initiation.
  • Severe concurrent medical condition that would prevent participation in study procedures
  • \<3 months
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Exercise Intervention Group then Adherence package group during follow-up phase

    Initially randomised to the exercise intervention group. Following completion of the exercise intervention, then randomised to receive the adherence support package.

    Other: Home-based, remotely delivered, supervised Exercise programme

  • Experimental
    Exercise Intervention Group then control group during follow-up phase

    Initially randomised to the exercise intervention group. Following completion of the exercise intervention, then randomised to the control group during the follow-up phase, so not given the adherence support package.

    Other: Home-based, remotely delivered, supervised Exercise programme

  • No intervention
    Control group, then the Adherence package group during the follow-up phase

    Initially randomised to the control group. Then randomised to receive the adherence support package in the follow-up phase

  • No intervention
    Control group, then also randomised to the control group in the follow-up phase

    Initially randomised to the control group. Following completion of the exercise intervention, then randomised to be in the control group in follow-up phase, so not given the adherence support package.

Interventions

  • OtherHome-based, remotely delivered, supervised Exercise programme

    A home-based remotely delivered supervised exercise programme

06

What researchers measure

Primary outcomes

  1. Six-minute walk distance

    Distance walked as measured during a six-minute walk test. Measured at around 6 months post-diagnosis to compare those from the exercise intervention group who have just completed their exercise programme, with the control group who have not yet had their exercise programme.

    Time frame: Around 6 months post diagnosis. (After completion of the exercise programme for those in the intervention group, and on medical therapy alone for those in the control group).

Secondary outcomes

  1. EmPHasis-10 questionnaire

    EmPHasis-10 quality of life questionnaire. Minimum value 0, Maximum value 50. Higher scores mean a worse outcome.

    Time frame: Around 6 months post diagnosis. (After completion of the exercise programme for those in the intervention group, and on medical therapy alone for those in the control group).

  2. NT-proBNP blood test

    NTproBNP blood test which is a marker of cardiac strain

    Time frame: Around 6 months post diagnosis. (After completion of the exercise programme for those in the intervention group, and on medical therapy alone for those in the control group).

  3. Patient Health Questionnaire-9

    Questionnaire validated for evaluating depression- completed by patients. Minimum value 0, Maximum value 27. Higher values indicated a worse outcome.

    Time frame: Around 6 months post diagnosis. (After completion of the exercise programme for those in the intervention group, and on medical therapy alone for those in the control group).

  4. Generalised Anxiety Disorder 7-item Scale

    Questionnaire validated for evaluating anxiety in patients- completed by patients. Minumum value 0, Maximum value 21. Higher scores indicate a worse outcome.

    Time frame: Around 6 months post diagnosis. (After completion of the exercise programme for those in the intervention group, and on medical therapy alone for those in the control group).

Other outcomes

  1. Exercise adherence rating scale

    Questionnaire validated for evaluating adherence to exercise in patients. Completed by patients. Minimum score 0, Maximum score 24. A higher score indicates better adherence.

    Time frame: This will be collected after patients complete the exercise programme and again at the end of their follow-up phase. For patients randomised to Study Group 1, this is at week 37 and week 89 from enrolment. For Study group 2, this is week 25 and week 77.

  2. Heart rate variability

    Variation in time between consecutive heart beats, collected by a smartwatch. Measured in milliseconds. Higher heart rate variability means better fitness and recovery.

    Time frame: This will be recorded during recorded sessions by the participant throughout study completion which is on average 83 weeks.

  3. Exercise Frequency

    Average number of recorded exercise sessions per week, measured as an absolute number. Higher number means more regular exercise.

    Time frame: This will be recorded during recorded sessions by the participant throughout study completion which is on average 83 weeks.

  4. Exercise Intensity

    Exercise intensity is recorded by the participant using a smartwatch during recorded exercise sessions. Exercise intensity is measured by the heart rate during exercise expressed as a percentage of the estimated maximum heart rate. The measure will be recorded as time spent in particular heart rate zones, expressed in hours and minutes. Zone 1: 50-60% of maximum heart rate. Zone 2: 60-70% of maximum heart rate. Zone 3: 70-80% of maximum heart rate. Zone 4: 80-90% of maximum heart rate. Zone 5: 90-100% of maximum heart rate. Longer time spent in higher heart rate zones means higher intensity exercise.

    Time frame: This will be recorded during recorded sessions by the participant throughout study completion which is on average 83 weeks.

  5. Sleep score

    Sleep score is measured by the smartwatch during sleep and expressed as an absolute value between 0-100. This is calculated based on sleep duration, stages (light, deep or rapid eye movement sleep), movement, and heart rate variability. Higher score means better rest.

    Time frame: This will be recorded throughout study completion which is on average 83 weeks.

  6. Step Count

    Number of steps walked by the participant each day, recorded by the smartwatch. Measured as an absolute value. Higher step count indicates higher activity levels.

    Time frame: This will be recorded throughout study completion which is on average 83 weeks.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • McCormack C, Kehoe B, Cullivan S, McCaffrey N, Gaine S, McCullagh B, McCarren A, Hardcastle SJ, Moyna NM. Safety, feasibility and effectiveness of the remotely delivered Pulmonary Hypertension and Home-Based (PHAHB) physical activity intervention. ERJ Open Res. 2024 Jan 8;10(1):00608-2023. doi: 10.1183/23120541.00608-2023. eCollection 2024 Jan. PubMed 38264149 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for Aug 2027, 16 months after the start.

Of 60 non-industry interventional studies with no phase under Pulmonary Arterial Hypertension, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 63. This study's planned 16 months is below that.

Counting every sponsor, half of 65 studies reached it within 42 months; a quarter within 18 and three quarters within 71.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 7, 2026
First posted
Jan 26, 2026
StartActual
Apr 2, 2026
Primary completionEst.
Aug 2027
CompletionEst.
Jan 2028
Last update
May 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07366879
Lead sponsor
Golden Jubilee National Hospital
Responsible party
Sponsor
First posted
Jan 26, 2026
Start date
Apr 2, 2026
Primary completion
Aug 2027 (estimated)
Completion
Jan 2028 (estimated)
Last update
May 13, 2026

Study contacts

Jamie Ingram, MBChB
Contact
jamie.ingram2@nhs.scot
0044 141-951-5440
Colin Church, BSc, MBChB, PhD, FRCP
Contact
colinchurch@doctors.org.uk
0044 141-951-5497

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion